AstraZeneca invests $30 million to upgrade production and supply base in China

AstraZeneca unveiled an investment of nearly 200 million yuan ($29.81 million) to upgrade its production and supply base in Wuxi, China, the company's Chinese unit said in a statement on Thursday.

The upgraded facility will be used for development and production of AstraZeneca's innovative cardiovascular drugs.

Covering a construction area of approximately 5,800 square meters, the project is scheduled to become operational in the fourth quarter of 2029 with an estimated annual capacity of 400 million tablets.